Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19
NCT ID: NCT05445531
Last Updated: 2022-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
111 participants
INTERVENTIONAL
2022-07-08
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The long-term consequences and spontaneous progression of these changes on imaging are completely unclear. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
NCT04990531
Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term Consequences
NCT04741412
MRI for Non-Invasive Imaging in Neonates and Children
NCT02163681
Pulmonary MRI Using Ultra Short /Zero TE Sequences
NCT06097741
Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI
NCT03198104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Early publications from the primarily affected Chinese provinces described rather mild, partly asymptomatic courses in children. This is consistent with the observation that the risk of severe COVID-19 disease increases steeply from the age of 70 years, and is also determined by the severity of obesity as well as other risk factors. Developmental expression of tissue factors may be one reason for the relative protection of younger patients from severe courses of the disease.
However, it is now becoming increasingly clear that some individuals with milder initial symptoms of COVID-19 may suffer from variable and persistent symptoms for many months after initial infection - this includes children. A modern low-field MRI is located in Erlangen, Germany. This technique has already been used to demonstrate persistent damage to lung tissue in adult patients after COVID-19. The device with a field strength of 0.55 Tesla (T) currently has the world's largest aperture (and is thus particularly suitable for patients with claustrophobia, among other things), a very quiet operating noise, and lower energy absorption in the tissue due to the weaker magnetic field than MRI scanners with 1.5T or 3T. This allows MRI imaging in a very broad pediatric population without the need for sedation.
To date, no structural changes were revealed by means of this MRI technique - however, large defects in the area of ventilation and blood flow function of the lung are apparent in specific functional sequences. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
Low-field magnetic resonance imaging
Functional and morphologic imaging of the lungs
Nailfold capillaroscopy
Imaging of nailfold microvasculature
Spiroergometry
Cardiopulmonary exercise testing
Realtime deformability cytometry
High-throughput measurement of cell deformability and physical properties
Recovered
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
Low-field magnetic resonance imaging
Functional and morphologic imaging of the lungs
Nailfold capillaroscopy
Imaging of nailfold microvasculature
Spiroergometry
Cardiopulmonary exercise testing
Realtime deformability cytometry
High-throughput measurement of cell deformability and physical properties
Long Covid
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
Low-field magnetic resonance imaging
Functional and morphologic imaging of the lungs
Nailfold capillaroscopy
Imaging of nailfold microvasculature
Spiroergometry
Cardiopulmonary exercise testing
Realtime deformability cytometry
High-throughput measurement of cell deformability and physical properties
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-field magnetic resonance imaging
Functional and morphologic imaging of the lungs
Nailfold capillaroscopy
Imaging of nailfold microvasculature
Spiroergometry
Cardiopulmonary exercise testing
Realtime deformability cytometry
High-throughput measurement of cell deformability and physical properties
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Long Covid criteria not met according to AWMF S1 guideline
* Positive SARS-CoV-2 infection confirmed by PCR
* Long Covid criteria not met according to AWMF S1 guideline
* Positive SARS-CoV-2 infection confirmed by PCR
* Long Covid criteria according to AWMF S1 guideline fulfilled
Exclusion Criteria
* Necessary quarantine
* Pregnancy, lactation
* Indication of acute infection
* Known pleural or pericardial effusion
* Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
* Marked thoracic deformities
* Previous lung surgery
* Injuries that do not allow for physical stress testing
* Refusal of MRI imaging
* General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
* History, clinical, or other suspicion of pulmonary disease
* Current respiratory infection/symptomatology
* Pain leading to respiratory limitation
* Inhaled therapy (e.g., steroids or beta-mimetics)
* Immunosuppression
* Any condition that may lead to respiratory limitation (e.g., pain disorder)
* Obesity (\>97% of age percentile)
Recovered arm:
* Acute SARS-CoV-2 infection and need for isolation
* Necessary quarantine
* Pregnancy, lactation
* Indication of acute infection
* Known pleural or pericardial effusion
* Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
* Marked thoracic deformities
* Previous lung surgery
* Injuries that do not allow for physical stress testing
* Refusal of MRI imaging
* General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Long Covid arm:
* Acute SARS-CoV-2 infection and need for isolation
* Necessary quarantine
* Pregnancy, lactation
* Indication of acute infection
* Known pleural or pericardial effusion
* Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
* Marked thoracic deformities
* Previous lung surgery
* Injuries that do not allow for physical stress testing
* Refusal of MRI imaging
* General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ferdinand Knieling, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Erlangen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Erlangen
Erlangen, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, Wechsler ME, Mak ACY, Eng C, Salazar S, Medina V, Wohlford EM, Huntsman S, Nickerson DA, Germer S, Zody MC, Abecasis G, Kang HM, Rice KM, Kumar R, Oh S, Rodriguez-Santana J, Burchard EG, Seibold MA. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020 Oct 12;11(1):5139. doi: 10.1038/s41467-020-18781-2.
Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J; HCA Lung Biological Network. Electronic address: [email protected]; HCA Lung Biological Network. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 May 28;181(5):1016-1035.e19. doi: 10.1016/j.cell.2020.04.035. Epub 2020 Apr 27.
Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Muhlberger E, Kotton DN. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7. doi: 10.1016/j.stem.2020.09.013. Epub 2020 Sep 18.
Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD. Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021 Jan 7;184(1):149-168.e17. doi: 10.1016/j.cell.2020.11.025. Epub 2020 Nov 19.
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-1665. doi: 10.1056/NEJMc2005073. Epub 2020 Mar 18. No abstract available.
Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.
Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, Kapp ME, Benjamin JT, Gulleman P, Nichols DS, Braunstein LZ, Hackett A, Koval M, Guttentag SH, Blackwell TS, Webber SA, Banovich NE; Vanderbilt COVID-19 Consortium Cohort; Human Cell Atlas Biological Network; Kropski JA, Sucre JM. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. J Clin Invest. 2021 Jan 4;131(1):e140766. doi: 10.1172/JCI140766.
Heiss R, Grodzki DM, Horger W, Uder M, Nagel AM, Bickelhaupt S. High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19. Magn Reson Imaging. 2021 Feb;76:49-51. doi: 10.1016/j.mri.2020.11.004. Epub 2020 Nov 18.
Shelmerdine SC, Lovrenski J, Caro-Dominguez P, Toso S; Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce. Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings. Pediatr Radiol. 2020 Aug;50(9):1217-1230. doi: 10.1007/s00247-020-04726-w. Epub 2020 Jun 18.
Duan YN, Zhu YQ, Tang LL, Qin J. CT features of novel coronavirus pneumonia (COVID-19) in children. Eur Radiol. 2020 Aug;30(8):4427-4433. doi: 10.1007/s00330-020-06860-3. Epub 2020 Apr 14.
Steinberger S, Lin B, Bernheim A, Chung M, Gao Y, Xie Z, Zhao T, Xia J, Mei X, Little BP. CT Features of Coronavirus Disease (COVID-19) in 30 Pediatric Patients. AJR Am J Roentgenol. 2020 Dec;215(6):1303-1311. doi: 10.2214/AJR.20.23145. Epub 2020 May 22.
Weigelt A, Akhundova G, Raming R, Tratzky JP, Regensburger AP, Kraus C, Waellisch W, Trollmann R, Woelfle J, Dittrich S, Heiss R, Knieling F, Schoeffl I. Light at the end of the tunnel? Follow-up of cardiopulmonary function in children with post-COVID-19. Eur J Pediatr. 2025 Jun 10;184(7):413. doi: 10.1007/s00431-025-06245-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-77-Bm
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.